| Features: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Piperlongumine (also called Piplartine), an alkaloid from long pepper fruit -Piperlongumine is a bioactive alkaloid derived from the long pepper (Piper longum) – Piperlongumine has been shown to selectively increase ROS levels in cancer cells. -NLRP3 inhibitor? -TrxR inhibitor (major antioxidant system) to increase ROS in cancer cells -ic50 cancer cells maybe 2-10uM, normal cells maybe exceeding 20uM. Available from mcsformulas.com -(Long Pepper, 500mg/Capsule)- 1 capsule 3 times daily with food -Piperlongumine Pro Liposomal, 40 mg-take 1 capsule daily with plenty of water, after a meal -Note half-life 30–60 minutes BioAv poor aqueous solubility and bioavailability Pathways: - induce ROS production in cancer cells likely at any dose. Effect on normal cells is inconclusive. - ROS↑ related: MMP↓(ΔΨm), ER Stress↑, UPR↑, Cyt‑c↑, Caspases↑, DNA damage↑, cl-PARP↑, Prx, - Lowers some AntiOxidant markers/ defense in Cancer Cells: but mostly raises NRF2 (raises antiO defense), TrxR↓(*important), GSH↓ Catalase↓ HO1↓ GPx↓ - Very little indication of raising AntiOxidant defense in Normal Cells: GSH↑, - lowers Inflammation : NF-kB↓, COX2↓, conversely p38↑, Pro-Inflammatory Cytokines : NLRP3↓, IL-1β↓, TNF-α↓, IL-6↓, IL-8↓ - inhibit Growth/Metastases : TumMeta↓, TumCG↓, EMT↓, MMP2↓, MMP9↓, VEGF↓, NF-κB↓, CXCR4↓, ERK↓ - reactivate genes thereby inhibiting cancer cell growth : HDAC↓(few reports), DNMT1↓, DNMT3A↓, EZH2↓, P53↑, HSP↓, Sp proteins↓, - cause Cell cycle arrest : TumCCA↑, cyclin D1↓, CDK2↓, CDK4↓, CDK6↓, - inhibits Migration/Invasion : TumCMig↓, TumCI↓, ERK↓, EMT↓, - small indication of inhibiting glycolysis : HIF-1α↓, cMyc↓, LDH↓, HK2↓, - inhibits angiogenesis↓ : VEGF↓, HIF-1α↓, EGFR↓, - Others: PI3K↓, AKT↓, JAK↓, STAT↓, β-catenin↓, ERK↓, JNK, - Synergies: chemo-sensitization, RadioSensitizer, Others(review target notes), Neuroprotective, Cognitive, Hepatoprotective, CardioProtective, - Selectivity: Cancer Cells vs Normal Cells
|
| Source: |
| Type: |
| MCP-1 (Monocyte Chemoattractant Protein-1, also known as CCL2) MCP-1/CCL2 is a chemokine involved in recruiting monocytes, memory T cells, and dendritic cells to sites of inflammation. – It plays a key role in mediating immune cell trafficking, inflammation, and tissue remodeling. MCP-1 is pivotal in inflammatory responses and can modulate immune cell infiltration into tissues. – It also influences the polarization of macrophages, which may adopt pro-inflammatory (M1) or anti-inflammatory/pro-tumoral (M2) roles. Many cancers (such as breast, prostate, ovarian, lung, and colon cancers) exhibit increased levels of MCP-1. – Both tumor cells and associated stromal cells (e.g., cancer-associated fibroblasts, infiltrating immune cells) can produce MCP-1, contributing to an inflammatory milieu. • Inducers of MCP-1: – Hypoxia, oncogenic pathways, and cytokine-rich environments (e.g., IL-1β, TNF-α) can drive increased MCP-1 expression. – This upregulation often correlates with an ongoing inflammatory response in the tumor microenvironment. |
| 3000- | PL, | Biological and physical approaches on the role of piplartine (piperlongumine) in cancer |
| - | in-vitro, | Nor, | HUVECs | - | in-vitro, | Laryn, | HEp2 |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:134 Target#:990 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid